Tweet This paper is perhaps interesting as we go into AAN week…All that will surface for the masses is the Conference abstract. For AAN they will all be published in the Journal Neurology, just as ECTRIMS abstracts are published in the Multiple Sclerosis Journal. The…
Using disease-modifying treatments shortly prior to or during pregnancy does not seem to increase the risk of neurodevelopmental disorders in exposed children, according to a real-world study of mothers with multiple sclerosis (MS). Still, sphingosine-1-phosphate (S1P) receptor modulators, which include therapies such as Gilenya (fingolimod),…
As I write this, the April showers that bring May flowers have brought forth a string of gloomy days here in central Texas. During days like these, I cannot help but be reminded of my grandma, who passed away about a year ago after a…
By Angel Blair When it comes to wellness and how we take care of our minds and bodies, there’s definitely some leeway as to what works for each person and what type of wellness is being referred to. If we’re … Continue reading → Source:…
A blood test being developed by Roche to measure a marker of nerve cell damage has received CE mark approval for the detection of neuroinflammation in people with relapsing-remitting multiple sclerosis (RRMS). Called Elecsys Neurofilament Light Chain (NfL), the test is designed to measure NfL…
Tweet This paper argues that if you look at blood cell counts it may help about look at disease activity. This view is perhaps abit controversial as there have been many studies looking at immune cell subsets circulating in the blood after a DMT and…
People with diabetes are significantly more likely — with nearly 60% higher odds — to develop multiple sclerosis (MS) than those without the metabolic disease, which is marked by high blood sugar levels, according to a new systematic review and meta-analysis. A significant association was…
I was outside with my youngest child, who was only a few months old, strapped to my back while doing yard work, housework, and everything else, while my husband, Rhead, lay on the couch inside. This had been going on for a couple of years…
The portable neuromodulation stimulator (PoNS), a noninvasive device that’s approved to improve walking and balance in people with multiple sclerosis (MS), has been acquired by Bioness Medical. The device was originally developed by Helius Medical Technologies, which rebranded to Solana in September of last year…
Tweet The Annual American Association of Neurology Junket is upon us and starts at the Weekend, NDG is there and may post us some of the stories but the abstracts are out now. What tickles your fancy about the important stories? I will be posting…